Global Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431682
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • Active Biotech Ab
  • Amgen
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ag
  • Genentech, Inc.
  • MORE
Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025, the global kidney cancer/ renal cell carcinoma drugs market was valued at US$ 3,302.3 Mn in 2016, and is expected to reach US$ 6,441.9 Mn by 2025, expanding at a CAGR of 8.1% from 2017 to 2025

Market Insights

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. According to American Cancer Society study in U.S. around 63,990 adults (40,610 men and 23,380 women) new cases of kidney cancer will be diagnosed. The average age of diagnosis is 64 and is rarely found in people under 45. It is estimated that 65% of people are diagnosed when the cancer is only located in the kidney and the 5-year survival rate is 93% in this group. The incidence of renal cell cancer is observed highest in Northern America and Europe. Almost 59%of kidney cancer cases is observed in developed countries. Thus, rising incidence of kidney cancer and entry of novel drug treatment are the key factors contributing to the growth of kidney cancer drug market.

The global kidney cancer drugs market is segmented by drugs type into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). Sutent dominates the global kidney cancer/renal cell carcinoma drugs market.

As of the current market scenario, North America dominates the global kidney cancer drugs market followed by the Europe. Rise in incidence of renal cancer, increasing geriatric population and novel drug treatment are key drivers for the growth of kidney cancer drug market in North America. Asia Pacific is the fastest growing regional market for kidney cancer drugs with highest CAGR in the forecast period. With improvement in diagnostic technology, rise in aged population and low cost production of drugs are some of the key factors contributing to the growth of Asia Pacific region.

Market Competition Assessment

Key players in the global kidney cancer drugs market are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., Glaxosmithkline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.

Key Market Movements:
  • Kidney cancer is the most common cancer observed falling within top ten most common cancer in both male and female. Rising incidence of kidney cancer due to adoption of unhealthy life style such as smoking, drinking and less physical activity. Thus increase in aged population and incidence of kidney cancer would propel the growth of kidney cancer drugs market.
  • Further approval of novel drugs would fuel the growth of global kidney cancer drugs market
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Active Biotech Ab
  • Amgen
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ag
  • Genentech, Inc.
  • MORE
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Kidney Cancer Drugs Market Portraiture
2.1.1. Global Kidney Cancer Drugs Market, by Drug Type, 2016
2.1.2. Global Kidney Cancer Drugs Market, by Geography, 2016

Chapter 3. Kidney Cancer Drugs: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Epidemiology of Kidney Cancer
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Kidney Cancer Drugs Market, by Type, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Kidney Cancer Drugs Market, by Type
4.3. Afinitor (Everolimus)
4.4. Avastin (Bevacizumab)
4.5. Cabomety (Cabozantinib)
4.6. Inlyta (Axitinib)
4.7. Nexavar (Sorafenib)
4.8. Proleukin (Aldesleukin)
4.9. Torisel (Temsirolimus)
4.10. Sutent (Sunitinib)
4.11. Votrient (Pazopanib)

Chapter 5. Global Kidney Cancer Drugs Market: Pipeline Analysis
5.1. Overview
5.1.1. Phase III (Market estimations by 2025)
5.1.1.1. Tivozanib
5.1.2. Phase II (Qualitative Information)
5.1.3. Phase I (Qualitative Information)
5.1.4. Preclinical Studies (Qualitative Information)

Chapter 6. Global Kidney Cancer Drugs Market, by Geography, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. North America Kidney Cancer Drugs Market Analysis, 2015 - 2025
6.2.1. North America Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.2.2. North America Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.1.1. U.S. Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.2.2.2. Canada
6.2.2.2.1. Canada Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.3. Europe Kidney Cancer Drugs Market Analysis, 2015 - 2025
6.3.1. Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.3.2. Europe Kidney Cancer Drugs Market, by Treatment Type, 2015 - 2025 (US$ Mn)
6.3.3. Europe Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.1.1. U.K. Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.3.3.2. Germany
6.3.3.2.1. Germany Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.3.3.3. Rest of Europe
6.3.3.3.1. Rest of Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.4. Asia Pacific Kidney Cancer Drugs Market Analysis, 2015 - 2025
6.4.1. Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.4.2. Asia Pacific Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.1.1. Japan Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.4.2.2. China
6.4.2.2.1. China Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.4.2.3. Rest of Asia Pacific
6.4.2.3.1. Rest of Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.5. Latin America Kidney Cancer Drugs Market Analysis, 2015 - 2025
6.5.1. Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.5.2. Latin America Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.1.1. Brazil Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.5.2.2. Mexico
6.5.2.2.1. Mexico Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.5.2.3. Rest of Latin America
6.5.2.3.1. Rest of Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.6. Middle East & Africa (MEA) Kidney Cancer Drugs Market Analysis, 2015 - 2025
6.6.1. MEA Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.6.2. MEA Kidney Cancer Drugs Market, by Region, 2015 - 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.1.1. GCC Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
6.6.2.2. Rest of MEA
6.6.2.2.1. Rest of MEA Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)

Chapter 7. Company Profiles
7.1. Active Biotech Ab
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product/Service Portfolio
7.1.4. Key Developments
7.2. Amgen
7.3. Bayer AG
7.4. Cipla Limited
7.5. F. Hoffmann-La Roche Ag
7.6. Genentech, Inc.
7.7. Glaxosmithkline Plc
7.8. Novartis Ag
7.9. Onyx
7.10. Pfizer, Inc.
7.11. Other Notable Players

List of Figures
Fig. 1 Kidney Cancer Drugs: Market Segmentation
Fig. 2 Global Kidney Cancer Drugs Market Share, by Drugs Type, 2016 (US$ Mn)
Fig. 3 Global Kidney Cancer Drugs Market, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition, by Geography
Fig. 5 Market Competition Landscape, by Key Players, 2016
Fig. 6 Global Sutent (Sunitinib)Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 7 Global Nexavar (Sorafenib)Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 8 Global Afinitor (Everolimus)Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 9 Global Votrient (Pazopanib)Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 10 Global Inlyta (Axitinib) Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 11 Global Avastin (Bevacizumab) Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 12 Global Torisel (Temsirolimus) Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 13 Global Proleukin (Aldesleukin) Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 14 U.S. Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 15 Canada Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 16 U.K. Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 17 Germany Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 18 Rest of Europe Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 19 Japan Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 20 China Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 21 Rest of Asia Pacific Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 22 Brazil Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 23 Mexico Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 24 Rest of Latin America Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 25 GCC Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)
Fig. 26 Rest of Middle East and Africa Kidney Cancer Drugs Market, 2015 - 2025 (US$ Mn)

List of Tables
Table 1 Global Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
Table 2 North America Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
Table 3 North America Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 4 Europe Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
Table 5 Europe Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 6 Asia Pacific Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
Table 7 Asia Pacific Kidney Cancer Drugs Market, by Country, 2015 - 2025(US$ Mn)
Table 8 Latin America Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025(US$ Mn)
Table 9 Latin America Kidney Cancer Drugs Market, by Country, 2015 - 2025 (US$ Mn)
Table 10 Middle East and Africa Kidney Cancer Drugs Market, by Drugs Type, 2015 - 2025 (US$ Mn)
Table 11 Middle East and Africa Kidney Cancer Drugs Market, by Region, 2015 - 2025 (US$ Mn)
Table 12 Active Biotech Ab: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 13 Amgen: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 14 Bayer AG: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 15 Cipla Limited: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 16 F. Hoffmann-La Roche Ag: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 17 Genetech, Inc.: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 18 Glaxosmithkline Plc: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 19 Novartis Ag: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 20 Onyx: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Table 21 Pfizer,Inc.: Company Snapshot (Business Description, Financial Information, Product/Service Portfolio, Key Developments)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Active Biotech Ab
  • Amgen
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ag
  • Genentech, Inc.
  • Glaxosmithkline Plc
  • Novartis Ag
  • Onyx
  • Pfizer, Inc.
  • Other Notable Players
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll